These findings suggest that either activating ATP2C1 or restoring the Mn-induced trafficking of ATP2C1 can reduce Mn accumulation, providing a possible target for treating HMDPC. Here, ATP2C1 is linked to cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome.